Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - lisdexamfetaminum dimesylate - hart hylki - 30 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - lisdexamfetaminum dimesylate - hart hylki - 50 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - lisdexamfetaminum dimesylate - hart hylki - 70 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - augnlækningar - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.